Michael Lainchbury - Concepedia

Author

Michael Lainchbury

Charles River Laboratories (United Kingdom)

Also Known As

M. Lainchbury, Michael D. Lainchbury, Michael Lainchbury

Publications

602

Citations

H-Index

Concepts

All Affiliations

Charles River Laboratories (United Kingdom)Institute of Cancer Research

About

Michael Lainchbury is an author at Charles River Laboratories (United Kingdom) specializing in pharmacology, medicine, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	193
2	Natural Sciences	2	2	64
3	Health Sciences	1	1	61
4	Biochemistry	1	1	30
5	Biomolecular Engineering	1	1	30

Michael Lainchbury

Publications

570

Citations

H-Index

Page 1

	Year	Citations
A Protecting Group Free Synthesis of (±)-Neostenine via the [5 + 2] Photocycloaddition of Maleimides Michael Lainchbury, Marcus I. Medley, Piers M. Taylor, The Journal of Organic Chemistry	2008	96
CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs Mike I. Walton, Paul D. Eve, Angela Hayes, Clinical Cancer Research	2012	92
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma Mike I. Walton, Paul D. Eve, Angela Hayes, Oncotarget ImmunologyPs296 Chk1PathologyCell DeathCancer Biology	2015	68
Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation Emily J. Hanan, Charles Eigenbrot, Marian C. Bryan, Journal of Medicinal Chemistry Broad Kinase SelectivityDrug TargetMolecular BiologyPharmacotherapyHts Hits	2014	61
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study Robert A. Heald, Krista K. Bowman, Marian C. Bryan, Journal of Medicinal Chemistry	2015	55
Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1) Bryan Chan, Eileen M. Seward, Michael Lainchbury, ACS Medicinal Chemistry Letters	2021	42
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (<i>R</i>)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737) James Osborne, Thomas P. Matthews, Tatiana McHardy, Journal of Medicinal Chemistry	2016	36
Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR Marian C. Bryan, Daniel J. Burdick, Bryan Chan, ACS Medicinal Chemistry Letters Molecular BiologyPharmacotherapyBroader KinomePharmaceutical ChemistryMedicinal Chemistry	2015	34
Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Bryan Chan, Emily J. Hanan, Krista K. Bowman, Journal of Medicinal Chemistry	2016	32
Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors Michael Lainchbury, Thomas P. Matthews, Tatiana McHardy, Journal of Medicinal Chemistry Tumor BiologyMedicinal ChemistryLead ScaffoldsBiochemistryCheckpoint Kinase 1	2012	30

Page 1